AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $1.61. This compares to loss of $1.59 per share a year ago.
Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 months Full clinical and translational data for rosnilimab in RA in Q2 2025 Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025 Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulator Announced exclusive global license agreement with Vanda Pharmaceuticals to develop and commercialize imsidolimab, an IL-36R antagonist Year-end 2024 cash and investments of ~$420 million and reiterating cash runway through year-end 2027 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a business update. “Rosnilimab's positive Phase 2b data in rheumatoid arthritis has revealed impressive safety, tolerability and three-month efficacy data that was sustained and surpasses six-month data from competitor all-active, head-to-head trials.
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review top-line data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist of PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Wednesday, Feb. 12, 2025, at 8:30am ET / 5:30am PT.
Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.